Moderna Settles COVID Vaccine Patent Dispute for Up to $2.25 Billion
In a major development for the biotech industry and global health sector, Moderna has agreed to settle a long running COVID Vaccine patent dispute for up to $2.25 billion. The agreement closes a key legal battle linked to its blockbuster mRNA based COVID 19 vaccine, widely known as Spikevax. This settlement is one of the…